CNS involvement in NSCLC: higher incidence in
EGFR
Mut + or
ALK+
ALK
+ patients treated
with crizotinib
6,7
EGFR
Mut+ patients treated
with first-generation TKI
3–5
All-comers
incidence of BM
1,2
BM 30%
(25–40%)
BM 40%
(30–60%)
BM 50%
Incidence of BM is higher:
•
Different tumor biology
•
Lack of drug penetration
•
Longer survival
1. Sørensen, et al. J Clin Oncol 1988 6(9): 1474–80; 2. Dempke, et al. Anticancer Res 2015 35(11): 5797–806
3. Omuro, et al. Cancer 2005 103(11): 2344–8; 4. Heon, et al. Clin Cancer Res 2010 16(23): 5873–82
5. Lee, et al. Cancer 2010 116(5): 1336–43; 6. Shaw, et al. Lancet Oncol 2011 12(11): 1004–12
7. Camidge, et al. Nat Rev Clin Oncol 2014 11(8): 473–81; Presented by Soria, et al. ASCO 2015 (discussant)
ALK, anaplastic lymphoma kinase
BM, brain metastases
CNS, central nervous system
EGFR, epidermal growth factor receptor
NSCLC, non-small-cell lung cancer
TKI, tyrosine kinase inhibitor.
